SK bioscience introduces 'glocalization' project

신하늬 2023. 5. 23. 18:11
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

닫기
The RVMC is an international framework kicked off during the World Economic Forum in Davos in May last year, with the goal of resolving inequality in the vaccine supply.

SK bioscience CEO Ahn Jae-yong, second from left, speaks during the Regionalised Vaccine Manufacturing Collaborative event held on Monday in Geneva, Switzerland. [SK BIOSCIENCE]

SK bioscience CEO Ahn Jae-yong, second from left, speaks during the Regionalised Vaccine Manufacturing Collaborative event held on Monday in Geneva, Switzerland. [SK BIOSCIENCE]

SK bioscience introduced its “glocalization” project aimed at ensuring equitable access to vaccines, during the Regionalised Vaccine Manufacturing Collaborative (RVMC) in Switzerland, the pharmaceutical company said Tuesday.

The RVMC is an international framework kicked off during the World Economic Forum in Davos in May last year, with the goal of resolving inequality in the vaccine supply.

Ahn Jae-yong, SK bioscience CEO, introduced the company’s glocalization project, which is one of the company's new business strategies. The project aims to establish local production facilities in regions with limited accessibility to vaccines, by transferring production capabilities, technologies and expertise to local authorities or companies.

The RVMC event was held in Geneva, Switzerland, during the 76th World Health Assembly, which runs from Sunday, May 21 to May 30.

BY SHIN HA-NEE [shin.hanee@joongang.co.kr]

Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.

이 기사에 대해 어떻게 생각하시나요?
코리아중앙데일리에서 직접 확인하세요. 해당 언론사로 이동합니다.